| Members |
targetComponentId |
| C/O - specified symptom findings |
Finding reported by subject or history provider (finding) |
| C1 esterase inhibitor 500 units powder for injection solution 8mL vial |
Product containing precisely human C1 esterase inhibitor 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
| CAP - NOS |
Contraceptive cap status (finding) |
| CAP - NOS |
Contraceptive cap status (finding) |
| CAP used from other agency |
Contraceptive cap status (finding) |
| CAP used from other agency |
Contraceptive cap status (finding) |
| CAT scan - NOS |
Computed tomography (procedure) |
| CDC Corynebacterium group G-1 |
Corynebacterium accolens |
| CDC group DF-2 |
Capnocytophaga canimorsus |
| CDE genotype |
CDE haplotype (finding) |
| CDe genotype |
CDe haplotype (finding) |
| CNS disorders NOS |
Disorder of the central nervous system (disorder) |
| CSF appearance - NOS |
Cerebrospinal fluid appearance |
| CSF cell content NOS |
Cell count, cerebrospinal fluid |
| CSF chemistry - general NOS |
Determination of general chemical content of cerebrospinal fluid (procedure) |
| CSF exam. - general NOS |
Determination of general chemical content of cerebrospinal fluid (procedure) |
| CSF examination NOS |
Cerebrospinal fluid examination |
| CSF pressure NOS |
Cerebrospinal fluid pressure |
| CSF: chloride level NOS |
CSF chloride measurement |
| CSF: electrophoresis NOS |
Cerebrospinal fluid protein electrophoresis (procedure) |
| CSF: globulin level NOS |
CSF globulin measurement |
| CSF: microorganisms NOS |
Identification of microorganisms in CSF |
| CSF: protein level NOS |
Measurement of protein in cerebrospinal fluid specimen (procedure) |
| CTV3 ROOT |
SNOMED CT Concept |
| CVS monitoring NOS |
Cardiovascular monitoring |
| CVS monitoring NOS |
Cardiovascular monitoring |
| Ca bone/joint cartilage NOS |
Malignant neoplasm of skeletal system (disorder) |
| Ca bone/joint cartilage NOS |
Malignant neoplasm of skeletal system (disorder) |
| Ca breast - NOS |
Malignant neoplasm of breast (disorder) |
| Ca breast - NOS |
Malignant neoplasm of breast (disorder) |
| Ca cervix screening NOS |
Cancer cervix screening status (finding) |
| Ca cervix screening NOS |
Screening for malignant neoplasm of cervix |
| Ca cervix uteri NOS |
Malignant neoplasm of cervix uteri |
| Ca cervix uteri NOS |
Malignant neoplasm of cervix uteri |
| Ca colon NOS |
Malignant neoplasm of colon (disorder) |
| Ca colon NOS |
Malignant neoplasm of colon (disorder) |
| Ca esophagus NOS |
Malignant neoplasm of oesophagus |
| Ca larynx - NOS |
Malignant neoplasm of larynx |
| Ca larynx - NOS |
Malignant neoplasm of larynx |
| Ca lip, oral, pharynx NOS |
Malignant neoplasm of lip, oral cavity and pharynx |
| Ca lip, oral, pharynx NOS |
Malignant neoplasm of lip, oral cavity and pharynx |
| Ca liver/biliary system NOS |
Carcinoma liver and/or biliary system (disorder) |
| Ca liver/biliary system NOS |
Carcinoma liver and/or biliary system (disorder) |
| Ca oesophagus NOS |
Malignant neoplasm of oesophagus |
| Ca pancreas NOS |
Malignant neoplasm of pancreas (disorder) |
| Ca pancreas NOS |
Malignant neoplasm of pancreas (disorder) |
| Ca rectum + Ca anus NOS |
Malignant neoplasm of anorectum (disorder) |
| Ca rectum + Ca anus NOS |
Malignant neoplasm of anorectum (disorder) |
| Ca skin - other NOS |
Malignant neoplasm of skin (disorder) |
| Ca skin - other NOS |
Malignant neoplasm of skin (disorder) |
| Ca stomach NOS |
Malignant neoplasm of stomach (disorder) |
| Ca stomach NOS |
Malignant neoplasm of stomach (disorder) |
| Ca uterus NOS: [carcinoma] or [cancer] |
Malignant neoplasm of uterus (disorder) |
| Ca uterus NOS: [carcinoma] or [cancer] |
Malignant neoplasm of uterus (disorder) |
| Cabbage - dietary |
Cabbage (substance) |
| Cabergoline [parkinsons] |
Product containing cabergoline (medicinal product) |
| Caesarean delivery - delivered |
Deliveries by caesarean |
| Caffeine and sodium benzoate injection |
Product containing caffeine and sodium benzoate (medicinal product) |
| Caffeine containing substance - non-pharmaceutical |
Caffeine |
| Café-au-lait spots and ring chromosome 11 |
Ring chromosome 11 syndrome |
| Calcaneum X-ray |
Plain X-ray of calcaneum |
| Calcaneum X-ray |
Plain X-ray of calcaneum |
| Calcipotriene 0.005%/betamethasone 0.064% topical suspension |
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 milliliter and calcipotriol 50 microgram/1 milliliter conventional release cutaneous lotion (clinical drug) |
| Calcitonin, salmon 100unit/mL injection solution 1mL vial |
Product containing precisely salmon calcitonin 100 unit/1 milliliter conventional release solution for injection (clinical drug) |
| Calcitonin, salmon 200iu/mL spray |
Product containing precisely salmon calcitonin 200 unit/1 actuation conventional release nasal spray (clinical drug) |
| Calcitonin, salmon 200unt/mL injection |
Salmon calcitonin 200 unit/mL solution for injection |
| Calcitonin, salmon 200unt/mL injection solution 2mL vial |
Salmon calcitonin 200 unit/mL solution for injection |
| Calcium analyte |
Calcium |
| Calcium antacid |
Calcium compound |
| Calcium carbonate+cholecalciferol 1.25g/11micrograms/sachet granules |
Calcium carbonate 6.25 mg/mL and colecalciferol 2.2 unit/mL oral solution |
| Calcium chloride 10% injection solution 10mL prefilled syringe |
Product containing precisely calcium chloride 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Calcium hydroxyapatite microsphere suspension in aqueous based carrier 0.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
| Calcium hydroxyapatite microsphere suspension in aqueous based carrier 1.3mL prefilled syringe |
Hydroxyapatite only product in parenteral dose form |
| Calcium phosphate+colecalciferol 3100mg/20micrograms/sachet powder for oral suspension |
Calcium phosphate and colecalciferol only product |
| Calculus - composition |
Calculus chemical composition - finding |
| Calculus analysis NOS |
Calculus analysis |
| Calculus analysis NOS |
Calculus analysis |
| Calculus chem. comp. NOS |
Determination of calculus chemical composition |
| Calculus chemical composition NOS |
Determination of calculus chemical composition |
| Calculus exam. general |
Calculus examination |
| Calculus examination NOS |
Calculus examination |
| Calculus examination NOS |
Calculus examination |
| Calculus examination general |
Calculus examination |
| Calculus gen. exam. NOS |
Calculus examination |
| Calculus general examination NOS |
Calculus examination |
| Calculus of bile duct with acute cholecystitis without obstruction |
Bile duct calculus with acute cholecystitis |
| Calculus of bile duct with chronic cholecystitis without obstruction |
Calculus of bile duct with chronic cholecystitis |
| Calculus of bile duct without obstruction |
Calculus of bile duct |
| Calculus of common bile duct with acute cholecystitis without obstruction |
Calculus of common bile duct with acute cholecystitis |
| Calculus of common bile duct with chronic cholecystitis without obstruction |
Calculus of common bile duct with chronic cholecystitis (disorder) |
| Calculus of common bile duct without obstruction |
Common bile duct calculus |
| Calculus of common duct without obstruction |
Common bile duct calculus |
| Calfactant intratracheal suspension 6mL vial |
Product containing only calfactant (medicinal product) |
| Calicivirus group |
Family Caliciviridae (organism) |
| Calliphora erythrocephala |
Calliphora vicina |
| Callitrogae |
Genus Cochliomyia (organism) |
| Callosity caused by prosthesis and/or appliance |
Callosity caused by device (disorder) |
| Caloric intake, function (observable entity) |
Energy intake (observable entity) |
| Caloscypha fulgens |
Caloscypha fulgens (organism) |
| Calymmatobacterium granulomatis |
Klebsiella granulomatis (organism) |
| Camouflaging preparations adverse reaction |
Adverse reaction (disorder) |